AUSTRALIAN TELETRIAL PROGRAM REACHES SIGNIFICANT MILESTONES IN TRIALS AND PARTICIPANTS From origins in Townsville to being national program across multiple disease states and populations
Filmed in Brisbane & Townsville, Queensland and Darwin, Northern Territory | November 2024
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
The program connects patients with researchers, medical professionals, and trial coordinators via video consultations and telehealth tools. This allows patients to receive treatment and follow-up care from their local healthcare providers, while still participating in high-quality clinical research.
Key Features of the Australian Teletrial Program:
- Remote Access to Trials: It facilitates the inclusion of patients from regional and remote areas who would otherwise have difficulty accessing clinical trials due to distance or travel constraints.
- Collaboration: The program involves partnerships between local healthcare providers, hospitals, research institutions, and trial sponsors. This collaborative model ensures that patients receive the best care and support throughout the trial process.
- Digital Health Technologies: Telehealth technologies, such as video conferencing, remote monitoring, and digital data collection, are used to manage patient care and ensure compliance with trial protocols.
- Widening Participation: It aims to diversify and increase the representation of regional and rural populations in clinical trials, which is important for trial results to include the broader population.
The Teletrial Program is part of a broader effort to improve the inclusivity and accessibility of medical research across Australia, ensuring that individuals, regardless of their location, have the opportunity to participate in cutting-edge clinical trials.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements:
- Being a proven program outside of oncology, with clinical specialties such as respiratory, cardiac, diabetes, sexual health, mental health filling a gap in service and equity.
- In regional, rural and remote places, with adults and paediatrics involved in the program, a higher than national average participation rate of clinical trials by First Nations peoples in satellite locations.
- Savings of time, money and distance for those patients to satellite sites.
- Having over a thousand participants in teletrials across the six jurisdictions.
- Established collaborative and supportive mechanism and network around education and training.
Australian Health Journal also spoke with Melanie Poxton, Assistant Director of Nursing at the program’s Queensland Regional Clinical Trials Coordinating Centre (QRCCC) in Townsville University Hospital, North Queensland and Heather Parker, the Northern Territory Australian Teletrial Program Manager with NT Health.
Produced in collaboration with the Australian Teletrial Program.
-
Implementing improvements in referral management and demand
Nalani Cox joined Gold Coast Health in 2019 as a Nurse Manager focused on improving referral management processes within the outpatient environment through the implementation of the Clinical Prioritisation Criteria. This work became a focus point for the organisation in 2020 when Nalani led an organisational wide change project introducing Smart Referrals, Refer Your Patient website and HealthPathways which has culminated in her position as the ADON of the Referral Strategy and Performance Department.
-
Cardinal Health brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.
-
Developing the nation’s first Health and Medical Research Strategy
Professor Steve Wesselingh serves as the CEO of NHMRC, having initially trained as an infectious diseases doctor. His career includes prominent roles such as Head of the Infectious Diseases Unit at the Alfred Hospital, Director of the Burnett, Dean of Medicine at Monash University, and the inaugural Director of SAHMRI. Under his leadership, NHMRC plays a critical role in funding health and medical research, allocating approximately a billion dollars annually to investigator-led projects, clinical trials, and various strategic initiatives. NHMRC also collaborates internationally with organisations such as the MRC and the EU, and manages grant allocation for the MRFF, which distributes $650 million each year.
